Business Standard

Dr Reddy's Lab rises 2.3%

Related News

The stock jumped 2.3 per cent to Rs 1,204.55 after the company said Phase-III clinical trial for its anti-diabetic molecule balaglitazone achieved the set parameters.

The company which conducted the study to determine the efficacy and safety of the drug, with Rheoscience — a subsidiary of said, it met its primary endpoint of reducing HbA1c or Glycoslated haemoglobin molecule, which indicates glucose level in blood. Besides, the oral anti-diabetic drug also showed effective results on fasting plasma glucose, oedeman and weight gain & body composition.

Read more on:   
|

Quick Links

 

Market News

Nickel down by 0.3% on global trend

Speculators trimmed positions amid a weak global trend

Zinc futures up 0.4% on spot demand; global cues

Speculators enlarged positions amidst a firming trend overseas

SpiceJet zooms as ex-promoter plans turnaround

Top sources in the ministry say investors are looking at pumping in around Rs 1,100 crore,

GMM Pfaudler hits record high on open offer by promoters

The promoter made an open offer to acquire 3.65 million or 25% stake in the company at price of Rs 245.85 per share.

Sensex, Nifty near day's high; RIL, L&T up 2%

The 30-share Sensex was up 339 points at 27,466 and the 50-share Nifty was up 95 points at 8,254.

Back to Top